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Background: Infections after liver transplantation are the main cause of death in the first year. Recent reports indicate
that NOD2 gene mutations increase the risk for inflammatory bowl disease and the severity of graft-versus-host disease in
bone marrow transplant patients. Data on polymorphisms in liver transplant patients are sparse. We analyzed 13
single-nucleotide polymorphisms (SNPs) of 13 different gene variants including the SNPs of NOD2 genes from liver
recipients. The aim of the study was to evaluate the impact of the SNPs on dialysis-dependent kidney failure, the
incidence of infections and patient survival.
Methods: During a period of 20-months, 231 patients were recruited in this non-interventional, prospective study.
Thirteen different SNPs and their impact on the patients’ survival, infection rate, and use of dialysis were assessed.
Results: NOD 2 wildtype genes were protective with respect to the survival of non-alcoholic, cirrhotic transplant patients
(3 year survival: 66.8% wildtype vs. 42.6% gene mutation, p = 0.026). This effect was not observed in alcoholic transplant
recipients.
The incidence of dialysis-dependent kidney failure and infection in the liver transplant patients was not influenced by
NOD 2 gene polymorphisms. No effect was noted in the remaining 12 SNPs.
Patients with early allograft dysfunction experienced significantly more infections, required dialysis and had significantly
worse survival.
In contrast, the donor-risk-index had no impact on the infection rate, use of dialysis or survival.
Conclusion: NOD2 gene variants seem to play a key role in non-alcoholic, liver transplant recipients. However these data
should be validated in a larger cohort.Background
Immunosuppression, as in liver transplant patients, car-
ries a high risk of life threatening infections such as
pneumonia or blood stream infections (BSI). Because
calcineurin inhibitors are used as immunosuppressive
agents to avoid organ rejection, infections have emerged
in the last 20 years as the main cause of death in the first
year after transplantation [1,2].
Several risk factors for infections after liver transplant-
ation (LTX) have been identified, such as being male sex,
having a prolonged cold ischemia time, acute liver failure,* Correspondence: fuat.saner@uni-due.de
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reproduction in any medium, provided the orrejection treatment, relaparotomy due to bleeding or bile,
and retransplantation within 30 days [3-5]. Recent reports
indicate that single nucleotide polymorphisms (SNPs) are
involved in a variety of diseases. Mutations of the toll-like
receptor 4 (TLR-4) genes are associated with an increased
incidence of inflammatory bowel disease due to bowl alter-
ations such as changes in the bacterial load and transloca-
tion [6], whereas TLR-4 mutations in bone-marrow
transplant patients are associated with an increased risk for
graft-versus-host disease (GvHD) [7]. Nucleotide oligomer-
isation domain 2 (NOD2) polymorphisms, as a part of the
innate immune system, have been shown to be protective
against GvHD [7]. Several SNPs in specific genes of liver
patients have been evaluated, with conflicting results. Man-
nose binding lectin (MBL) in the donor was found to carrytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[8,9]. Another clinical study indicates that an MBL gene
polymorphism was associated with an increased risk for the
development of hepato-cellular carcinoma in chronic hepa-
titis C patients [10]. The TLR 2 and TLR4-receptors are as-
sumed to recognize hepatitis C virus. The association
between TLR polymorphisms and outcome after trans-
plantation due to chronic hepatitis C infection was evalu-
ated in a clinical study [11]. The authors found that a
homozygous TLR 2 polymorphism was associated with a
higher incidence of poor graft function and higher
mortality.
NOD2 gene polymorphism is associated with an in-
creased incidence of liver and intestine failure in patients
following combined liver and small bowl transplantation
[12].
Recently, a group from Rotterdam [13] evaluated 50
polymorphisms in 181 liver transplant patients and their
corresponding donors with respect to organ rejection
and infections in the recipient. They found no correl-
ation between the gene variants and bacterial and/or
fungal infections.
The aim of our study was to evaluate the impact of 13
different SNPs, including in NOD2 and TLR 4, on
transplant-associated complications such as infection,
need for dialysis and the outcomes of the recipients.
Methods
During the observation period of 2/2009 to 1/2012, a total
of 231 patients were recruited in this prospective, non-
interventional study. All patients received liver transplanta-
tions at the Medical Center University Essen, Department
of General -, Visceral- and Transplant Surgery.
All patients were transplanted with whole liver from a
brain-dead donor.
Exclusion criteria were recipient age ≤ 18 years and
lack of a blood sample from the recipient.
This study was conducted in accordance with the
amended Declaration of Helsinki. Local institutional re-
view boards of the University Essen approved the proto-
col, and written informed consent was obtained from all
patients.
Surgical procedure and postoperative patient care
All transplants were accomplished with a liver from a
deceased donor. Standardized surgical techniques were
used for all recipients as was a strict anesthetic protocol.
A cell saver system was used for all patients who did
not have hepatocellular carcinoma. Postoperatively, all
patients were treated at a single intensive care unit
(ICU) with standardized ICU treatment.
For immunosuppression, the patients received tacrolimus
(0,1 mg/kg/d with a targeted plasma level of 5–8 ng/ml),
mycophenolatmofetil (1000 mg twice a day) andintraoperative prednisolone (10 mg/kg, followed by 40 mg/
day), which was gradually tapered within the 6 weeks after
liver transplantation. Rejection episodes were treated with
intravenous prednisolone (500 mg, 3 times/day).
Intraoperative antibiotic prophylaxis included intra-
venous ampicillin/sulbactam (3 grams), which was re-
peated if the operation time was longer than 3 hours. If
there were no signs of infection, the antibiotic treatment
was stopped after the surgical procedure. Selective di-
gestive decontamination or fungal prophylaxis was not
administered to the patients. A preventive treatment
with valgancyclovir was performed in almost all patients,
but not when both the donor and recipient were CMV
IgG negative.
Definitions
Infections (pneumonia and blood stream infections
[BSI]) were diagnosed based on the criteria proposed by
the Centers for Disease Control [14], as already de-
scribed in one of our previously published studies [2].
Briefly, the diagnosis of pneumonia was based on the
presence of pulmonary infiltrates together with clinical
symptoms suggestive of a lower respiratory tract infec-
tion, the identification of a relevant etiologic microbial
agent, and the absence of an alternative diagnosis during
follow-up. Detection of Aspergillus spp. in the broncho-
alveolar lavage was regarded as relevant and was ad-
equately treated.
The diagnosis of BSI was defined as the isolation of
gram-positive cocci, gram-negative rods, or any type of
fungi in the blood culture.
Sepsis and pneumonia were summarized as clinical
significant infections (CSI).
Mortality was defined as death from any cause during
the hospital stay or within 1 year after discharge.
Early allograft dysfunction (EAD) was based on the
EAD assessment published in 2010 [15]. Briefly, EAD
was defined as: Bilirubin ≥10 mg/dL on postoperative
day 7 and/or INR ≥1.6 on postoperative day 7 and/or
AST or ALT >2000 IU/L within the first 7 days.
The donor-risk index (DRI) was assessed as previously
described by Feng et al. [16].
Polymorphism genotyping
DNA was prepared from the PBMCs obtained from the re-
cipient after transplantation using the Magna Pure device
from Roche diagnostics (Mannheim Germany). Genotyping
for the NOD2/CARD15 gene (SNP8, R702W, rs2066844,
SNP12, G908R, rs2066845 and SNP 13, 1007 fs, rs2066847)
was performed with a Taqman protocol, as published previ-
ously [7,17]. Genotyping for TLR 4 (D299G; rs4986790)
and TLR 4 (T399I; rs4987233) was performed and then an-
alyzed using hybridization probes and primers, as previ-
ously published [18]. The call rate in a Taqman Genotyper
Table 2 Diagnosis leading to transplantation
Diagnosis Number of patients
Alcoholic related cirrhosis 60
Hepatitis C 63
Hepatitis B 22
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was 90% for each. All tested polymorphisms are listed in
Table 1.
The fluorescence-labeled sensor and anchor hybridization
probes for the Lightcycler protocol and Taqman probes
were purchased from TIB MOLBIOL (Berlin, Germany).
Sensor probes cover for the SNPs and exhibit a different
temperature depending on binding to the wild type or
variant allele. Anchor probes were designed to display a
significantly higher melting temperature compared with
the corresponding sensor probes. PCR and subsequent
melting curve analysis were performed using software for
the Lightcycler device. Control samples were included in
each run [17].
We included the allele and genotype of the examined
SNPs with prefabricated LightSNiP arrays (TIB MOL-
BIOL GmBH, Berlin, Germany). The 96-well array was
company technically with the plate configuration like
NOD2, TLR1,-4,-9 and other SNPs compiled. The candi-
date genotypes were selected mainly based on the litera-
tures that were available on 2009/2010 when the study
was initially designed. The allele frequencies are com-
pared with reference population (www.ncbi.nlm.nih.gov
and www.hapmap.org) for Caucasian. Genotype prob-
abilities can then be calculated using Hardy-Weinberg
equilibrium (HWE) assumption or other assumptions
that relate allele frequencies to the allele frequencies.
Statistical analysis
Continuous data are given as the mean with the stand-
ard deviation (SD). Dichotomous or categorical variables
are given as numbers with percentage. Differences in
continuous variables were calculated using the student’s
t-test and differences in categorical variables were com-
pared using the Pearson’s Chi squared test. Kaplan-
Meier curves were constructed. A p-value < 0.05 wasTable 1 Polymorphisms (SNPs) tested in all liver
transplant patients
IL 23R rs11209026










NOD2 L1007F insC rs20666847
NOD2 R702W rs2066844considered statistically significant. Statistical analysis was
performed using SPSS statistical software version 20.0
for Mac (SPSS Inc, Chicago III, USA).
Results
Clinical characteristics and post-transplant clinical signifi-
cant infections
From 2/2009 – 01/2012, a total of 231 post-liver trans-
plant patients (67.5% m, 32.5% f) were recruited into the
study.
The diagnosis leading to liver transplantation were
given in Table 2.
The CSI rate was 26.4%, which significantly affected
the ventilation time; stay in the ICU; the incidence of
dialysis use; and survival rate. The median ventilation
time for patients with CSI was 198 h (8–3035 h) com-
pared to 20 h (0–617) in patients without CSI (p <
0.0001). CSI resulted in a median ICU stay of 18 days
(2–130), which was significantly longer than the 4 days
(1–27) in patients without CSI (p < 0.0001). The inci-
dence of dialysis-dependent kidney failure increased
from 26.4% in patients without infections to 60.6% in pa-
tients with CSI (p < 0.0001). The rate of dialysis in the
whole cohort was 32.3%. Table 3 details the clinical and
demographic characteristics of both cohorts, patients
with and without CSIs.
The 1-year survival rate decreased in patients with
CSIs to 42% compared with 83.7% in patients without
infection (p = 0.0001). The 1-year-survival for all patients
was 72.6%.Non-alcoholic-steatohepatitis (NASH) 15
Acute liver failure 7
Primary sclerosing cholangitis 11
Cryptogenic 12





Secondary sclerosing hepatitis 7
Primary biliary cirrhosis 3
Miscellaneous 8
Total 231
Miscellaneous: Budd-Chiari Syndome (1); Amyloidosis (2), Cholangiocellular
carcinoma (1); Embryonal sarcoma (1); Neuroendocrine tumor (1), secondary
biliary cirrhosis (1); alpha 1 antitrypsine deficiency (1).
Table 3 Clinical variables and characteristics for both






Age 52 ± 9 53 ± 10 0.8
MELD 21 ± 9 25 ± 11 0.006
Ventilation time (in hours) 20 (0–617) 198 (8–3035) < 0.001
ICU stay (days) 4 (1–27) 18 (2–130) < 0.001
Hospital stay (days) 21 (2–136) 42 (3–244) < 0.001
Incidence of EAD 18.2% 38.7% < 0.001
DRI 1.8 ± 0.38 1.7 ± 0.36 0.16
WIT (min) 34 ± 12 33 ± 7 0.7
CIT (min) 427 ± 136 461 ± 154 0.1
Incidence of Dialysis 26.4% 60.6% < 0.001
CSI: clinical significant infections.
ICU: intensive care unit.
EAD: early allograft dysfunction.
DRI: donor-risk-index.
WIT: warm ischemia time.
CIT: cold ischemia time.
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infection or survival rates. Patients with CSI had a
significantly higher lab MELD than patients without
CSI (25 ±10 vs. 21 ± 9, p = 0.006).
EAD after transplantation affected both the CSI and
survival rates. The CSI rate in patients with EAD was
38.7% compared to 18.2% (p = 0.001) in patients with-
out EAD. Survival decreased from 78.1% to 64.7%
(p = 0.023) in patients with severe infection.Table 4 Characteristics of genes and polymorphisms → patie
Gene Allele rs number Wild type genotype
n (%)
IL23R G/A 11209026 44 (85)
IL18 RAP A/G 917997 25 (48)
CARD9 G/A 4077515 21 (40)
NOD2 C/T 2066844 40 (77)
NOD2 G/C 2066845 48 (80)
NOD2 -/C 2066847 47 (90)
TLR1 G/C 5743611 32 (62)
TLR4 299 G/A 4986790 50 (96)
TLR4 399 G/A 4987233 48 (92)
TLR9 1237 C/T 5743836 16 (31)
TLR9 1486 T/C 187084 31 (61)
NQO1 609 C/T 1800566 41 (79)
CYP1B1 432 G/C 1056836 16 (31)
MTHFR 677 T/C 1801133 23 (45)
MTHFR 1298 C/A 1801131 18 (41)Genetic polymorphisms in the non-interventional study
group and their impact on infection and survival
The allele and genotype distribution of the SNPs in the
different groups (alcoholic and non-alcoholic) were
given in the Tables 4 and 5.
Non-alcoholic patients received a survival benefit from
NOD 2 with wild type variants. Non-alcoholic patients with
wild type NOD2 genes had a one-year survival rate of
75.4%, whereas the patients with polymorphisms had a sur-
vival rate of 49.7% (p = 0.026) (Figure 1). The difference be-
tween wild type NOD2 and polymorphism variants became
significant at 6 months after transplantation. This was not
the case in alcoholic patients who received liver transplants.
The observed 1-year survival in patients with alcoholic dis-
ease and a genetic polymorphism for NOD 2 was 83%,
which was higher than that in the NOD2 wild type group
(64%), but this did not reach statistical significance. The
overall survival for the whole population (alcoholic and
non-alcoholic patients) was 72.7% for the wild type NOD2
vs. 62.5% for the genetic polymorphism (p = 0.45). Table 6
presents the clinical characteristics of the non-alcoholic
and alcoholic patients. Patients with non-alcoholic disease
were significantly older and required significantly more dia-
lysis treatment.
NOD-2 polymorphism did not affect the incidence of in-
fection (28.6% vs. 30.3%) or incidence of dialysis (33.2% vs.
30.3%). However, NOD 2 polymorphism seems to be pro-
tective against EAD. Patients with NOD-2 wild type devel-
oped EAD in 44.3% of the cases, whereas patients with the
gene variant had a moderate EAD incidence of 24.2%
(p = 0.024).nts (Pts) with alcoholic liver failure
Heterozygote genotype Homozygote mutation Pts
n (%) n (%)
8 (15) 52
23 (44) 4 (8) 52
23 (44) 8 (15) 52
12 (23) 52
10 (17) 2(3) 60
4 (8) 1 (2) 52
14 (27) 6 (12) 52
1 (2) 1 (2) 52
3 (6) 1 (2) 52
27 (53) 8 (16) 51
19 (37) 1 (2) 51
9 (17) 2 (4) 52
20 (39) 15 (30) 51
22 (43) 6 (12) 51
23 (52) 3 (7) 44
Table 5 Characteristics of genes and polymorphisms → patients (Pts) with non-alcoholic liver failure
Gene Allele rs number Wild type genotype Heterozygote genotype Homozygote mutation Pts
n (%) n (%) n (%)
IL23R G/A 11209026 138 (93) 11 (7) 149
IL18 RAP A/G 917997 75 (51) 61 (41) 12 (8) 148
Card9 G/A 4077515 59 (40) 67 (45) 22 (15) 148
NOD2 C/T 2066844 128 (86) 21 (14) 149
NOD2 G/C 2066845 138 (81) 22 (13) 11 (6) 171
NOD2 -/C 2066847 145 (97) 3 (2) 1 (1) 149
TLR1 G/C 5743611 82 (55) 56 (38) 11 (7) 149
TLR4 299 G/A 4986790 128 (86) 19 (13) 2 (1) 149
TLR4 399 G/A 4987233 130 (87) 18 (12) 1 (1) 149
TLR9 1237 C/T 5743836 50 (34) 68 (46) 29 (20) 147
TLR9 1486 T/C 187084 90 (61) 47 (32) 10 (7) 147
NQO1 609 C/T 1800566 92 (62) 47 (31) 10 (7) 149
CYP1B1 432 G/C 1056836 59 (40) 63 (42) 26 (18) 148
MTHFR 677 T/C 1801133 58 (39) 66 (45) 23 (16) 147
MTHFR 1298 C/A 1801131 67 (53) 42 (33) 18 (14) 127
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results in the evaluated parameters.
Discussion
Our study indicates that wild type NOD2 confers a sur-
vival benefit to non-alcoholic patients who receive a liver
transplant. We recorded a 36% higher survival in pa-
tients with the wild type gene variants compared to the
NOD 2 mutation gene variants in this cohort. However,
these results were not reproducible for patients with al-
coholic disease. In contrast, in patients with alcoholic
disease, the gene variant of NOD2 seems to increase sur-
vival, though this finding was not statistically significant.
Patients with alcoholic disease were significantly older
according to statistical analysis, but the difference of 3
years (55 vs. 52 years) seems clinically negligible.
EAD is a serious complication after liver transplant-
ation, which is associated with a higher retransplantation
rate and higher mortality [19-21]. EAD was almost 2
times more common in patients with non-alcoholic dis-
ease compared to alcoholic patients who received a liver
transplant. However, the protective effect of the NOD2
gene with wild type variants overruled the EAD effect.
Recent reports have provided evidence that NOD2
gene variants influence the severity of graft-versus-host-
disease (GVHD) and the transplant survival in bone
marrow transplant (BMT) patients.
The Elmaagacli group demonstrated a significantly
higher incidence of GVHD in patients with gene variants
of NOD2 following BMT compared with patients who
had wild type NOD2 [7]. These data are in agreementwith a study by Holler et al. [22] in which there was an
increased risk of GVHD in patients with an NOD2 gene
variant. The authors also reported an increased risk of
mortality with the gene variant, which is in contrast with
the findings of the Elmaagacli group [7].
The Pittsburgh group evaluated the NOD 2 gene vari-
ant in simultaneous liver and small bowel transplanted
pediatric patients [12]. They reported that NOD2 gene
variants were associated with increased liver and intes-
tinal failure in patients with short-gut syndrome.
Although NOD2, as a part of the innate immune sys-
tem, plays a key role in preventing bacterial infections,
we did not find a difference among patients with and
without CSI. Moreover, NOD2 mutations were not asso-
ciated with a decreased incidence of dialysis use; wild
type NOD2 in non-alcoholic patients may have an inde-
pendent protective effect for survival.
More than a quarter of our patients experienced CSI,
which was associated with significantly higher rates of
dialysis use, longer ventilation time, length of ICU – and
hospital stay, and higher mortality. In an earlier study
conducted by our department, the rate of CSI (pneumo-
nia and sepsis) was 32.3% (24% sepsis rate and 8.3%
pneumonia rate) [2]. The reason for the higher CSI rate
may be related to a different patient population. While
only patients with a postmortem organ were recruited in
the current study, 24% of patients in the previous study
were transplanted with a graft from a living donor. Bil-
iary complications, including bile leaks, which are asso-
ciated with sepsis, range from 0.3 - 22% in whole organ
transplantation [23,24], which is significantly lower than
Figure 1 Presents the 1-year survival of patients who received liver transplants for non-alcoholic liver disease. The wild type NOD2 is
protective with respect to the survival rate in this cohort. The 1–year survival rate for patients with wild type NOD2 was 75.4% compared to
49.2% in patients with the gene variant.
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Some groups reported biliary complications in split liver
transplantation of up to 60% [25], which may contribute
to a lower sepsis rate in the current study despite a
higher MELD score compared with our own data in the
last decade.Table 6 Clinical variables in alcoholic and non-alcoholic patie
Non-alcoholic disease
age 52 ± 10
CIT (minutes) 447 ± 145
WIT (minutes) 33 ± 9
MELD 22 ± 9
Incidence of EAD 44.4%
Incidence of CSI 25.7%
Incidence of Dialysis 35.3%
DRI 1.8 ±0.4
Ventilation time (hours) 35 (0–1681)
ICU stay (days) 5.5 (1–71)
Hospital stay 23.5 (2–244)
ICU: Intensive Care Unit.
EAD: early allograft dysfunction.
DRI: donor-risk-index.
WIT: warm ischemia time.
CIT: cold ischemia time.
CSI: clinical significant infections.A recently published study [26] evaluated the risk fac-
tors for infections in 367 patients. The authors reported
a CSI (pneumonia and blood stream infection) rate of
28.8%, which is similar to the incidence in our study. In
line with this study, Sganga et al. [27] identified a blood
stream infection rate of 28%. Unfortunately, neithernts
Alcoholic disease P value
55 ± 8 0.017
406 ± 124 0.048
34 ± 15 0.7
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tion. Our study indicated a nearly 50% decrease in the
one-year-survival for patients who develop a CSI, which
is significantly higher than in other groups. Sun et al.
[28] evaluated the risk factors for infections in the
MELD era. The group stated that the recipient age
(OR =1.09) and the MELD score affect infection. They
reported an overall (patients with and without infections)
one-year survival rate of 76.7% in the Pre-MELD era and
82.5% in the MELD era. In our study, the one-year sur-
vival rate was 72.3% for all patients. The MELD scores
in both studies were comparable, but there is a differ-
ence of 10% in the one-year survival of all patients,
which may be related to the quality of the donor graft.
While in the UNOS region, only 32% of the transplanted
grafts have a DRI of > 1.5; this rate accounts for 65% in
the EUROTRANSPLANT region. Moreover, only 6% of
the transplanted organs in the UNOS region have a
DRI > 2, but 23% in the EUROTRANSPLANT area have
a DRI > 2, which is associated with a higher graft failure
and lower patient survival [29]. This may in part explain
the higher mortality.
There are several studies reporting a worse outcome of
liver transplantation in patients with kidney dysfunction
and dialysis [30-32]. The registry data of liver transplant pa-
tients with postoperative kidney dysfunction demonstrate a
significantly worse 2-year survival compared with patients
with adequate or mild kidney dysfunction (55% vs. 76%,
p < 0.05) [33]. These data are in line with a retrospective
study that evaluated the risk factors in terms of the survival
rate after liver transplantation [34]. Patients with dialysis-
dependent kidney failure had a one-year survival of less
than 50%.
These data are comparable with our study. Sixty-
six percent of patients with CSI had dialysis-
dependent kidney failure, which was associated with
a one-year survival 64.7%. Sun et al. reported of a
dialysis-dependent kidney failure in less than 10% of
their transplanted patients. In contrast to that study,
32.3% of our patients required dialysis treatment due
to kidney failure, which affects their outcomes. In
this context, it is indispensible to highlight the sig-
nificantly higher dialysis rate in patients with non-
alcoholic disease than in alcoholic patients in our
cohort. Despite this fact, wild type NOD2 was pro-
tective in this patient cohort with respect to their
long-term survival.
Our study has some limitations. First, it was a single-
center study. Because we conducted an observational
study, there is no real control group. We did not stratify
or evaluate the patients’ outcomes with respect to the
transplant surgeon or anesthesia team. However because
2007 we have had a constant dedicated surgery and
anesthesia team who take care for these patients.Conclusion
In conclusion, our data indicates wild type NOD2 offers a
survival benefit in liver transplant patients with non-
alcoholic disease. Patients with the NOD2 gene variant
should have closer follow-up as part of the standard of care.
The other SNPs that we tested did not significantly influ-
ence the CSI and survival rates in this cohort. Transplant-
related factors may be more dominant risk factors for these
patients than the genetic polymorphisms.
Key messages
1. NOD2 gene polymorphism is associated with higher
mortality in patients non-alcoholic disease.
2. DRI has no impact on infection and survivial.
3. EAD is associated with significantly more CSI.
4. Patients with CSI had a significant worse 1-year sur-
vival, more common dialysis treatment, longer venti-
lation time, and longer ICU stay compared to
patients without infection.
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